Injectable preparation	
1-(4-trifluoromethyl-2-pyridinyl)piperazine	15 mg
NaOH/HCl	to pH 5
mannitol	to isotonic
water for injections	to 1 ml
dissolve the components, adjust to volume and pH.	

Freeze-dried injectable preparations

The same components as for the injectable preparation were dissolved and adjusted to pH 5, and the solution was freeze-dried.

Capsule	
active component	50 mg
HPC	3 mg
corn starch	15 mg
magnesium stearate	1,5 mg
lactose	to 150 mg
The components were processed as for the tablet and the resulting mass was filled into capsules.	
Suppository	
compound of example 1	5 mg
whitepsol 558	500 mg
The wax was melted and the active compound was dissolved therein.	

We claim:

1. Pharmaceutical composition that is useful as a medicinal product comprising customary pharmaceutical excipients and an effective amount for treating disorders of the central nervous system by 5HT1B type serotoninergic agonist activity of at least one compound of formula



in which a trifluoromethyl substituent is at the 4-position, at the 5-position, or at 4- and 5-positions of the pyridinyl ring, and the substituent R denotes either hydrogen or halogen substituent at positions of the pyridinyl ring not occupied by CF_3, or a pharmaceutically acceptable salt thereof.

2. Pharmaceutical composition according to claim 1, comprising 1-(5-tri-fluoromethyl-2-pyridinyl piperazine or a pharmaceutically acceptable salt thereof.

3. Pharmaceutical composition according to claim 1, comprising 1-(4-tri-fluoromethyl-2-pyridinyl piperazine or a pharmaceutically acceptable salt thereof.

4. A compound or a pharmaceutically acceptable salt thereof of the formula



in which a trifluoromethyl substituent is at the 4-position, at the 5-position, or 4- and 5-positions of the pyridinyl ring, an the substituent R denotes either hydrogen or a halogen substituent at positions of the pyridinyl ring not occupied by CF_3, and their pharmaceutically acceptable salts, with the proviso that R denotes a halogen when only one trifluoromethyl substituent is present.

5. Compound according to claim 4, selected from the group consisting of 1-(3-chloro-5-trifluoromethyl-2-pyridinyl)-piperazine, 1-(4,5-bis(tri-fluoromethyl)-2-pyridinyl)-piperazine, and 1-(5-trifluoromethyl-6-chloro-2-pyridinyl)-piperazine, or a pharmaceutically acceptable salt thereof.

6. Method for treating disorders of the central nervous system through 5HT1B type serotoninergic agonist activity comprising administering pharmaceutically effective amounts of at least one compound of the formula



in which a trifluoromethyl substituent is at the 4-position, at the 5-position, or at 4- and 5-positions of the pyridinyl ring, and the substituent R denotes either hydrogen or a halogen substituent at positions of the pyridinyl ring not occupied by CF_3, or a pharmaceutically acceptable salt thereof.

* * * * *